CAS: 13535-01-8; 5-Bromopyridin-3-Amine

上下游产品

CAS号625-92-3 3,5-二溴吡啶 | CAS号20826-04-4 5-溴烟酸 | CAS号39620-02-5 5-溴吡啶-3-羰酰氯 | CAS号15862-30-3 3-溴-5-硝基吡啶 | CAS号626-55-1 3-溴吡啶 | CAS号1083326-19-5 N-(5-溴吡啶-3-基)环丙烷磺酰胺 | CAS号1083326-18-4 N-(5-溴-3-吡啶基)-甲磺酰胺 | CAS号31676-54-7 3-氨基-5-苯基吡啶 | CAS号407-20-5 3-溴-5-氟吡啶 | CAS号361550-43-8 5-溴吡啶-3-甲酸叔丁酯 | CAS号212332-40-6 3-溴-5-异丙氧基吡啶 | CAS号873302-39-7 N-(5-溴吡啶-3-基)-2... | CAS号74115-13-2 3-溴-5-羟基吡啶 | CAS号15862-46-1 N-(5-溴吡啶-3-基)乙酰胺 | CAS号1084-12-4 N-(5-溴-3-吡啶)苯磺酰胺

5-溴吡啶-3-羰酰氯置于氨,溴,Sodium Hydroxide体系中,用 二氯甲烷,水 用作溶剂,化学反应 1.25H,反应生成5-溴-3-氨基吡啶
参考文献:发现7-芳基取代的(1,5-萘啶-4-基)脲作为极光激酶抑制剂
标题:发现7-芳基取代的(1,5-萘啶-4-基)脲作为极光激酶抑制剂
摘要:作为我们确定具有生物学意义的新化学实体的研究项目的一部分,我们开发了一种合成方法以及对(7-芳基-1,5-萘并吡啶-4-基)脲作为一种新型的aurora激酶抑制剂进行生物学评估的研究基于病理性细胞增殖的恶性疾病的治疗.1,5-萘啶衍生物对aurora激酶a和b具有极好的抑制活性,而活性最高的化合物1-环丙基-3-[7-(1-甲基-1 H-吡唑-4-基)-1,5萘啶-4-基尿素(49),显示的ic 50值为13和107 N M分别针对aurora激酶a和b.此外,强调了对一组七种与癌症相关的蛋白激酶的选择性.还确定了体外adme特性,以合理化将抗增殖活性与aurora激酶抑制相关联的困难.最后,这些化合物的非常好安全性为它们作为抗癌药的进一步发展提供了有希望的潜力.
Doi:10.1002/cmdc.201300384

专利信息

专利号:US-10995078-B2
优先权日:2013-03-13
标 题:Compounds and compositions for inhibition of FASN
发明人：BAIR KENNETH W; LANCIA JR DAVID R; LI HONGBIN; LOCH JAMES; LU WEI; MARTIN MATTHEW W; MILLAN DAVID S; SCHILLER SHAWN E R; TEBBE MARK J
权利人:FORMA THERAPEUTICS INC
摘要:The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

专利号:US-2009196912-A1
优先权日:2004-07-30
标 题:Pyridinylamines
发明人：EICKHOFF JAN ELKE; HAFENBRADL DORIS; SCHWAB WILFRIED; COTTON MATTHEW; KIEBL BERT MATTHIAS; ZECH BIRGIT; MULLER STEFAN; HARRIS JOHN; SAVIC VLADIMIR; MACRITCHIE JACKIE
权利人:GPC BOTECH AG
摘要:Described are pyridinylamines and pharmaceutically acceptable salts thereof, the use of these pyridinylamines for the prophylaxis and/or treatment of various diseases such as infectious diseases, including opportunistic infections, prion diseases immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as pharmaceutical compositions containing at least one pyridinylamine and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the pyridinylamines are disclosed.

专利号:CN-111732493-A
优先权日:2017-01-16
标题 :A kind of synthesis technique of aromatic amine compound

专利号:CN-111732493-B
优先权日:2017-01-16
标题:A kind of synthesis technique of aromatic amine compound